Anti-CTLA-4 Antibody Formulation Stability via Chelating Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
CTLA-4 antibody formulations face challenges with chemical and physical stability, leading to potential product loss due to degradation over time, necessitating improved formulations that maintain biological activity and shelf life.
Innovation Solution
A liquid pharmaceutical composition comprising monoclonal anti-CTLA-4 antibodies with a pharmaceutically acceptable chelating agent, such as EDTA, which enhances stability by reducing aggregation, fragmentation, oxidation, and freeze/thaw instability, while maintaining antibody activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If CTLA-4 antibody formulations are stored under expected conditions, then shelf life is extended, but chemical and physical degradation occurs over time
Solution Approach 1:
The patent modifies the formulation parameters by incorporating specific excipients including chelating agents (EDTA, DTPA), antioxidants (methionine, ascorbic acid), surfactants (polysorbate 80, poloxamer 188), and buffers (acetate, citrate, phosphate) to optimize chemical and physical stability. These parameter changes enable the antibody to maintain stability over extended storage periods while preserving biological activity.
2Productivity
If CTLA-4 antibody formulations are concentrated to reduce product loss, then productivity increases, but aggregation and fragmentation increase
Solution Approach 1:
The patent introduces intermediary substances that mediate between the concentrated antibody and degradation pathways. Chelating agents sequester metal ions that catalyze oxidation, antioxidants directly scavenge free radicals, and surfactants form protective complexes around the antibody molecules. These intermediaries enable high-concentration formulations to remain stable by intercepting degradation mechanisms before they can cause aggregation or fragmentation.
3Ease of operation
If CTLA-4 antibody formulations undergo freeze/thaw cycles, then ease of operation improves, but biological activity decreases
Solution Approach 1:
The formulation incorporates protective agents that cushion the antibody against freeze/thaw stress before damage occurs. Cryoprotectants like sucrose and trehalose form glassy matrices that prevent ice crystal formation and protect protein structure during freezing. Antioxidants and chelating agents are pre-positioned to neutralize reactive species generated during thawing, thereby preserving biological activity through subsequent freeze/thaw cycles.
4Reliability
If CTLA-4 antibody formulations are exposed to oxidation, then chemical stability deteriorates, but product loss increases
Solution Approach 1:
The patent converts the harmful oxidation process into a beneficial protective mechanism. Antioxidants like methionine and ascorbic acid sacrifice themselves by preferentially reacting with oxidizing agents, converting potentially damaging oxidation into harmless byproducts. Chelating agents sequester pro-oxidant metal ions, transforming them from harmful catalysts into benign complexes. This approach protects the antibody from oxidation-induced product loss while maintaining chemical stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves improved chemical and physical stability of CTLA-4 antibodies, extending shelf life and maintaining biological activity, with reduced degradation even under accelerated storage conditions.
Implementation Method 1
A liquid pharmaceutical composition comprising monoclonal anti-CTLA-4 antibodies with a pharmaceutically acceptable chelating agent, such as EDTA
Data Source
AI summary
The present invention provides for novel compositions of anti-CTLA-4 antibodies comprising a chelating agent. Also provided are method of treating diseases and conditions with novel compositions of CTLA-4 antibodies, including various neoplasia conditions.